EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Inhalable and thermo-responsive, fat-encased nanoparticles have been developed by researchers at the University of Sydney as possible treatment for lung cancer. The team has recently designed inhalable, targetable particles that can attack tumors but leave healthy cells undamaged, reducing the side effects of cancer treatment. The particles consist of a drug encased in a lipid…
Daily aspirin use among seniors may double their risk of developing a particularly advanced form of age-related macular degeneration, a debilitating eye disease, a large new European study suggests. The possible link involves the so-called “wet” type of age-related macular degeneration (AMD), a significant cause of blindness in seniors. http://www.nlm.nih.gov/medlineplus/news/fullstory_120483.html
Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities. “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…
Tuberculosis experts at Johns Hopkins and elsewhere have closely mimicked how active but untreated cases of the underlying lung infection lead to permanent eye damage and blindness in people.Lead study investigator and Johns Hopkins infectious disease specialist Petros Karakousis, M.D., says the new animal model should hasten development of a badly needed, early diagnostic test…
By combining data on optometry patient’s eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. The results, reported in the journal PLOS Computational Biology, show precisely how a small protein that can both damage or grow blood vessels in the eye causes vision loss and…
Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial. The cell-based approach taken is intended to rescue sick and dying…